Zhejiang Medicine Co Ltd (600216) Income Statement

An income statement shows a company's revenue, expenses, and profit over a reporting period.

Zhejiang Medicine Co., Ltd. manufactures and sells life nutrition and pharmaceuticals products in China and internationally. The company offers synthetic vitamin E, vitamin A, natural vitamin E, ß-carotene, canthaxanthin, vancomycin hydrochloride, teicoplanin, and daptomycin.

Total Revenue Chart for Zhejiang Medicine Co Ltd

Zhejiang Medicine Co Ltd (600216) revenue for FY2025 was CNY 8.9B, a -5.3% change from FY2024. Zhejiang Medicine Co Ltd's revenue grew from CNY 763.6M in 1996 to CNY 8.9B in 2025 (1063.0% over 29 years). Earnings per share grew from CNY 0.03 in 2000 to CNY 1.09 in 2021 (4134.9%). Revenue compound annual growth rate: 5-year CAGR of 3.9%, 10-year CAGR of 7.0%, 20-year CAGR of 8.1%.

The most recent 8 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Revenue (CNY)

R&D as % of Revenue

Compare with

Key Stats

Market Cap
¥10.22B
Implied Share Price
¥10.63
Enterprise Value
¥7.37B
Revenue (TTM)
¥8.43B
EBITDA
¥1.32B
Profit Margin
7.51%
Trailing P/E
16.11
Forward P/E
13.39
Price/Book (MRQ)
0.89
Price/Sales (TTM)
1.21
EV/EBITDA
12.39
EV/Revenue
0.87
Dividend Yield
2.64%
Book Value
¥11.84
Free Cash Flow (FY2025)
¥1.44B
Free Cash Flow Yield
14.08%

Snapshot as of 30th October 2026 — not point-in-time controlled, may lag the live market by a few days.